Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations
J LoPiccolo, GM Blumenthal, WB Bernstein… - Drug Resistance …, 2008 - Elsevier
The PI3K/Akt/mTOR pathway is a prototypic survival pathway that is constitutively activated
in many types of cancer. Mechanisms for pathway activation include loss of tumor …
in many types of cancer. Mechanisms for pathway activation include loss of tumor …
[HTML][HTML] Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non–small-cell lung cancer
V Papadimitrakopoulou - Journal of Thoracic Oncology, 2012 - Elsevier
Lung cancer is a common disease with more than 1.6 million new cases diagnosed
worldwide in 2008. Treatments for patients with advanced disease are rarely curative, and …
worldwide in 2008. Treatments for patients with advanced disease are rarely curative, and …
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in …
JJ Gills, J LoPiccolo, J Tsurutani, RH Shoemaker… - Clinical cancer …, 2007 - AACR
Purpose: The development of new cancer drugs is slow and costly. HIV protease inhibitors
are Food and Drug Administration approved for HIV patients. Because these drugs cause …
are Food and Drug Administration approved for HIV patients. Because these drugs cause …
miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non–small cell lung cancer
AKT signaling is constitutively activated in various cancers, due in large part to loss-of-
function in the PTEN and PHLPP phosphatases that act as tumor suppressor genes …
function in the PTEN and PHLPP phosphatases that act as tumor suppressor genes …
[HTML][HTML] Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer
PY Yip - Translational lung cancer research, 2015 - ncbi.nlm.nih.gov
Non-small cell lung cancer (NSCLC) is a devastating disease with poor prognosis. Systemic
chemotherapy has been the mainstay of treatment in advanced disease for many decades …
chemotherapy has been the mainstay of treatment in advanced disease for many decades …
Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer
EE Vincent, DJE Elder, EC Thomas, L Phillips… - British journal of …, 2011 - nature.com
Background: The activity of the protein kinase Akt is frequently dysregulated in cancer and is
an important factor in the growth and survival of tumour cells. Akt activation involves the …
an important factor in the growth and survival of tumour cells. Akt activation involves the …
Activation of Akt predicts poor outcome in neuroblastoma
D Opel, C Poremba, T Simon, KM Debatin, S Fulda - Cancer research, 2007 - AACR
Whereas aberrant activation of the phosphatidylinositol 3′-kinase (PI3K)/Akt pathway, a
key survival cascade, has previously been linked to poor prognosis in several human …
key survival cascade, has previously been linked to poor prognosis in several human …
Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non–small cell lung cancer
A Yoshizawa, J Fukuoka, S Shimizu, K Shilo… - Clinical Cancer …, 2010 - AACR
Purpose: The eukaryotic translation initiation factor complex 4E (eIF4E) is downstream in the
mammalian target of rapamycin (mTOR) pathway. This study explored expression of eIF4E …
mammalian target of rapamycin (mTOR) pathway. This study explored expression of eIF4E …
Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment
H Cheng, M Shcherba, G Pendurti, Y Liang… - Lung cancer …, 2014 - Taylor & Francis
SUMMARY The PI3K/AKT/mTOR pathway is commonly activated in non-small-cell lung
cancer. It plays important roles in promoting oncogenesis in lung cancer and mediating …
cancer. It plays important roles in promoting oncogenesis in lung cancer and mediating …
Targeting AKT/PKB to improve treatment outcomes for solid tumors
The serine/threonine kinase AKT, also known as protein kinase B (PKB), is the major
substrate to phosphoinositide 3-kinase (PI3K) and consists of three paralogs: AKT1 (PKBα) …
substrate to phosphoinositide 3-kinase (PI3K) and consists of three paralogs: AKT1 (PKBα) …